https www okebet com login

https www okebet com login Russian President Vladimir Putin said on Friday that Russia would keep testing its new Oreshnik hypersonic missile in combat and had a stock ready for use, while Ukraine said it was already at work to develop air systems to counter the weapon. Putin, 72, was speaking a day after Russia fired the new intermediate-range weapon into Ukraine for the first time, a step he said was prompted by Ukraine’s use of US ballistic missiles and British cruise missiles to hit Russia. Ukrainian President Volodymyr Zelensky said Kyiv was working with its Western partners to work out systems to counter “new risks.” Putin described the first use of Oreshnik (hazel tree) as a successful test, and said more would follow. “We will continue these tests, including in combat conditions, depending on the situation and the nature of the security threats that are created for Russia,” he said in televised comments to defense officials and missile developers. “Moreover, we have a stock of such products, a stock of such systems ready for use.” A US official, however, said the weapon Russia used was an experimental one. The official said Russia has a limited number of them and that this is not a capability that Russia is able to regularly deploy on the battlefield. Intermediate missiles have a range of 1,860-3,415 miles, which would enable them to strike anywhere in Europe or the western United States from Russia. Security experts said the novel feature of the Oreshnik missile was that it carried multiple warheads capable of simultaneously striking different targets – something usually associated with longer-range intercontinental ballistic missiles designed to carry nuclear warheads. Ukraine said the missile reached a top speed of more than 8,000 mph and took about 15 minutes to reach its target from its launch. The firing of the missile was part of a sharp rise in tensions this week as both Ukraine and Russia have struck each other’s territory with increasingly potent weapons. Moscow says that by giving the green light for Ukraine to fire Western missiles deep inside Russia, the U.S. and its allies are entering into direct conflict with Russia. On Tuesday, Putin approved policy changes that lowered the threshold for Russia to use nuclear weapons in response to an attack with conventional weapons. Zelensky, speaking in his nightly video address, has described Russia’s use of the new missile as an escalation. “On my behalf, the Minister of Defense of Ukraine is already holding meetings with our partners regarding new air defense systems capable of protecting lives from new risks,” he said. “When someone starts using other countries not only for terror, but also for testing their new missiles through acts of terror, then this is clearly an international crime.” Ukrainians, he said, had to remain vigilant. “We must be aware that ‘comrade’ Putin will keep trying to intimidate us,” he said. “That is how he built all his power.” The Kremlin said the firing of the Oreshnik was a warning to the West against taking further “reckless” actions and decisions in support of Ukraine. The Oreshnik was fired with conventional, not nuclear warheads. Putin said it was not a strategic nuclear weapon but its striking power and accuracy meant that its impact would be comparable, “especially when used in a massive group and in combination with other high-precision long-range systems.” He said the missile could not be shot down by an enemy. “I will add that there is no countermeasure to such a missile, no means of intercepting it, in the world today,” he said.”And I will emphasize once again that we will continue testing this newest system. It is necessary to establish serial production.”AP News Summary at 5:09 p.m. ESTMutual of America Capital Management LLC grew its position in Bio-Techne Co. ( NASDAQ:TECH – Free Report ) by 27.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,673 shares of the biotechnology company’s stock after acquiring an additional 8,852 shares during the period. Mutual of America Capital Management LLC’s holdings in Bio-Techne were worth $3,331,000 at the end of the most recent quarter. Other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in Bio-Techne by 92.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company’s stock worth $404,470,000 after purchasing an additional 2,755,065 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Bio-Techne by 20.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,714,994 shares of the biotechnology company’s stock worth $122,879,000 after acquiring an additional 290,510 shares during the period. Mackenzie Financial Corp increased its holdings in shares of Bio-Techne by 8.2% during the 2nd quarter. Mackenzie Financial Corp now owns 2,862,260 shares of the biotechnology company’s stock worth $205,081,000 after acquiring an additional 216,044 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Bio-Techne by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,589,799 shares of the biotechnology company’s stock valued at $185,559,000 after acquiring an additional 88,257 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Bio-Techne by 9.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 894,352 shares of the biotechnology company’s stock valued at $64,082,000 after purchasing an additional 76,641 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several equities analysts have commented on the stock. Scotiabank upped their price objective on shares of Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a report on Thursday, October 31st. StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Robert W. Baird boosted their price objective on Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Royal Bank of Canada lowered their target price on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 8th. Finally, Benchmark restated a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a research note on Tuesday, August 13th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.78. Bio-Techne Stock Performance NASDAQ:TECH opened at $71.28 on Friday. The company has a market cap of $11.33 billion, a price-to-earnings ratio of 75.61, a PEG ratio of 4.84 and a beta of 1.28. Bio-Techne Co. has a fifty-two week low of $61.16 and a fifty-two week high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 4.56. The stock has a fifty day moving average price of $73.84 and a 200-day moving average price of $75.28. Bio-Techne ( NASDAQ:TECH – Get Free Report ) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $289.46 million for the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.35 earnings per share. As a group, equities analysts anticipate that Bio-Techne Co. will post 1.68 EPS for the current fiscal year. Bio-Techne Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Monday, November 11th were given a dividend of $0.08 per share. The ex-dividend date was Friday, November 8th. This represents a $0.32 annualized dividend and a yield of 0.45%. Bio-Techne’s dividend payout ratio is currently 34.04%. About Bio-Techne ( Free Report ) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. Featured Articles Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter .

Trump says he can't guarantee tariffs won't raise prices, won't rule out revenge prosecutions

Nico Iamaleava throws 4 TD passes to lead No. 10 Tennessee over UTEP 56-0

NEW YORK — There's a Christmas Day basketball game at Walt Disney World, featuring Mickey, Minnie, Goofy and Wemby. An animated game, anyway. The real game takes place at Madison Square Garden, where Victor Wembanyama and the San Antonio Spurs face the New York Knicks in a game televised on ABC and ESPN and streamed on Disney+ and ESPN+. The special alt-cast, the first animated presentation of an NBA game, will be shown on ESPN2 and also stream on Disney+ and ESPN+. Madison Square Garden is a staple of the NBA's Christmas schedule. Now it merges with a bigger home of the holidays, because the "Dunk the Halls" game will be staged at Disney, on a court set up right smack in the middle of where countless families have posed for vacation photos. Why that location? Because it was Mickey Mouse's Christmas wish. "Basketball courts often have the ability to make a normal environment look special, but in Disney it can only turn out incredible," Wembanyama said in an ESPN video promoting his Christmas debut. The story — this is Disney, after all — begins with Mickey penning a letter to Santa Claus, asking if he and his pals can host a basketball game. They'll not only get to watch one with NBA players, but some of them will even get to play. Goofy and Donald Duck will sub in for a couple Knicks players, while Mickey and Minnie Mouse will come on to play for the Spurs. "It looks to me like Goofy and Jalen Brunson have a really good pick-and-roll at the elite level," said Phil Orlins, an ESPN vice president of production. Walt Disney World hosted real NBA games in 2020, when the league set up there to complete its season that had been suspended by the COVID-19 pandemic. Those games were played at the ESPN Wide World of Sports. The setting for the Christmas game will be Main Street USA, at the entrance of the Magic Kingdom. Viewers will recognize Cinderella's castle behind one baseline and the train station at the other end, and perhaps some shops they have visited in between. Previous alternate animated broadcasts included an NFL game taking place in Andy's room from "Toy Story;" the "NHL Big City Greens Classic" during a game between the Washington Capitals and New York Rangers; and earlier this month, another NFL matchup between the Cincinnati Bengals and Dallas Cowboys also taking place at Springfield's Atoms Stadium as part of "The Simpsons Funday Football." Unlike basketball, the players are helmeted in those sports. So, this telecast required an extra level of detail and cooperation with players and teams to create accurate appearances of their faces and hairstyles. "So, this is a level of detail that we've never gone, that we've never done on any other broadcast," said David Sparrgrove, the senior director of creative animation for ESPN. Wembanyama, the 7-foot-3 phenom from France who was last season's NBA Rookie of the Year, looks huge even among most NBA players. The creators of the alternate telecast had to design how he'd look not only among his teammates and rivals, but among mice, ducks and chipmunks. "Like, Victor Wembanyama, seeing him in person is insane. It's like seeing an alien descend on a basketball court, and I think we kind of captured that in his animated character," said Drew Carter, who will again handle play-by-play duties, as he had in the previous animated telecasts, and will get an assist from sideline reporter Daisy Duck. Wembanyama's presence is one reason the Spurs-Knicks matchup, the leadoff to the NBA's five-game Christmas slate, was the obvious choice to do the animated telecast. The noon EST start means it will begin in the early evening in France and should draw well there. Also, it comes after ABC televises the "Disney Parks Magical Christmas Day Parade" for the previous two hours, providing more time to hype the broadcast. Recognizing that some viewers who then switch over to the animated game may be Disney experts but NBA novices, there will be 10 educational explainers to help with basketball lingo and rules. Beyond Sports' visualization technology and Sony's Hawk-Eye tracking allow the animated players to make the same movements and plays made moments earlier by the real ones at MSG. Carter and analyst Monica McNutt will be animated in the style of the telecast, donning VR headsets to experience the game from Main Street, USA. Other animated faces recognizable to some viewers include NBA Commissioner Adam Silver, who will judge a halftime dunk contest among Mickey and his friends, and Santa himself, who will operate ESPN's "SkyCam" during the game. The players are curious how the production — and themselves — will look. "It's going to be so crazy to see the game animated," Spurs veteran Chris Paul said. "I think what's dope about it is it will give kids another opportunity to watch a game and to see us, basically, as characters." Get local news delivered to your inbox!